Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Malignant Melanoma

Free Subscription 02.02.2026 2 Am J Dermatopathol 1 BMC Cancer 2 Br J Dermatol 2 Eur J Dermatol 1 J Immunol 4 Melanoma Res 2 Nat Med 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Dermatopathol

1. LI Y, Hutchison DM, Linden KG, Lee BA, et al
   Diagnostic Utility of Molecular Profiling in a Giant Cellular Blue Nevus.
   Am J Dermatopathol. 2026;48:94-99.
   PubMed         Abstract available
   
   
2. WOOD BA, Shepard S, James C, Harvey NT, et al
   BAP1-Inactivated Melanocytic Tumors With Distinctive p16-Negative Clonal Growth and Liver Metastases.
   Am J Dermatopathol. 2025 Nov 14. doi: 10.1097/DAD.0000000000003151.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. ZHAO M, Zhao L, Yang Y, Wang F, et al
   Correction to: Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.
   BMC Cancer. 2026;26:139.
   PubMed        
   
   

   
   Br J Dermatol

4. QI J, Nie G
   Comment on 'Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden'.
   Br J Dermatol. 2026 Jan 28:ljag030. doi: 10.1093.
   PubMed        
   
   
5. AHMED S, van Bodegraven B, Proby C, Harwood CA, et al
   Ethnicity and the epidemiology of skin cancer incidence: a national retrospective population-based study in England, 2013-20.
   Br J Dermatol. 2025 Sep 10:ljaf352. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Eur J Dermatol

6. BORIK-HEIL L, Holler C, Bohler K, Brunner M, et al
   Successful adjuvant nivolumab therapy in a toddler with xeroderma pigmentosum and stage III melanoma.
   Eur J Dermatol. 2025;35:529-531.
   PubMed        
   
   
7. POSSANNER C, Spurny-Dworak J, Breier F, Stella A, et al
   Long-lasting effects of the COVID-19 pandemic on the incidence and depth of malignant melanoma.
   Eur J Dermatol. 2025;35:471-476.
   PubMed         Abstract available
   
   

   
   J Immunol

8. HUANG P, Wang H, Guan X, Pu R, et al
   UTY coordinates with UTX to repress NK cell development and maturation in males.
   J Immunol. 2026;215:vkaf248.
   PubMed         Abstract available
   
   

   
   Melanoma Res

9. STRATIGOS IA, Dessinioti C, Nikolaou V, Befon A, et al
   Divergent pathways of melanoma development: evidence from a Southern European cohort.
   Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001075.
   PubMed         Abstract available
   
   
10. BILIK SM, Burke OM, Elman SA
    Chromosome 1p13.2 gene cluster upregulation in neuroblastoma RAS viral oncogene homolog pathogenic variant melanoma: a potential biomarker axis.
    Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001080.
    PubMed         Abstract available
    
    
11. KISSINGER CR, Miller DJ, Li Z, Ashraf UM, et al
    Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.
    Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001077.
    PubMed         Abstract available
    
    
12. DUARTE-BATEMAN D, Escandon JM, Shen A, Chen Y, et al
    Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials.
    Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001079.
    PubMed         Abstract available
    
    

    
    Nat Med

13. DUTTAGUPTA S, Messaoudene M, Hunter S, Desilets A, et al
    Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
    Nat Med. 2026 Jan 28. doi: 10.1038/s41591-025-04186.
    PubMed         Abstract available
    
    
14. HOEIJMAKERS LL, Dimitriadis P, Wijnen SCMA, Reijers ILM, et al
    Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
    Nat Med. 2026 Jan 28. doi: 10.1038/s41591-025-04158.
    PubMed         Abstract available
    
    

    
    PLoS One

15. SELVARAJ KJ, Damian DL, Lyons JG, Wilmott JS, et al
    A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol.
    PLoS One. 2026;21:e0339476.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.